Effect of Healthy Family Program on Population Blood Pressure

March 2, 2026 updated by: Heart Health Research Center

Effect of Healthy Family Program on Population Blood Pressure: A 1:1 Parallel Design, Multi-Center Cluster Randomized Trial

This is a 1:1 parallel design, multi-center, cluster-randomized control trial. A total of 80 villages in Ruyang County, Henan Province, China, will be randomly assigned to the intervention group or control group. At least 100 participants from 30-50 families in each village will be included in this study. The intervention group will engage in a variety of strategies, including educating a healthy lifestyle, adopting a low-sodium diet, managing weight, participating in physical exercise, monitoring blood pressure, and undergoing antihypertensive treatment. These efforts will be led by family health instructors from the community. The control group will receive usual care. The primary endpoint of this study is the change of systolic blood pressure from baseline to 6 months, reported as the difference between intervention and control group.

Study Overview

Status

Completed

Detailed Description

This cluster-randomized control trial aims to randomly allocate 80 villages in Ruyan County to either receive a multifaceted intervention led by family health instructors or continue with usual care. Each village will recruit around 100 individuals aged 40-80 years, with or without hypertension. In intervention villages, a blood pressure management team, headed by family health instructors and family leaders, will implement various strategies including promoting a low-sodium diet, weight management, physical exercise, blood pressure monitoring, and administering antihypertensive treatment. The intervention will span 6 months, followed by another 6-month follow-up period. The primary hypothesis posits that the mean systolic blood pressure change from baseline to 6 months will be higher in the intervention group compared to the control group. The objective of this "Health Family Program" is to evaluate the efficacy of a non-healthcare provider-led multifaceted intervention in enhancing healthy lifestyles and managing blood pressure among rural residents, regardless of their hypertension status, in China.

Study Type

Interventional

Enrollment (Actual)

8001

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Henan
      • Luoyang, Henan, China
        • Ruyang County People's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

  1. Village screening:

    Villages were eligible for inclusion if they had ≥200 permanent households, with ≥60 households comprising ≥2 family members.

  2. Inclusion and Exclusion Criteria for the Family

Inclusion Criteria:

  1. At least 2 participants between the age of 40-80 years meet the inclusion and exclusion criteria of family members and willing to participate in this study;
  2. At least one family member can use the smartphone to upload BP values.

Exclusion Criteria:

  1. Any family member participated in the other hypertension-related programs;
  2. Inappropriate for the study decided by the healthy family instructor.

3.Inclusion and Exclusion Criteria for the Family Member

Inclusion Criteria:

  1. 40-80 years old, regardless of BP level and antihypertensive treatment;
  2. No travel plan for more than 1 month during the study period;
  3. Written or fingerprinted informed consent form.

Exclusion Criteria:

  1. Significant cognitive dysfunction;
  2. With advanced tumor, dialysis, or other serious diseases;
  3. Lying in bed for a long time or unable to take care of themselves;
  4. Diagnosed of secondary hypertension;
  5. Having birth plans in the next six months, pregnant or lactating women;
  6. Other ineligible circumstances judged by the investigators.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Usual care
Residents in this group will receive usual lifestyle and health care management.
Experimental: Multifaceted intervention
Residents in this group will receive multifaceted intervention including education for a healthy lifestyle, free provision of sodium substitute, weight management, physical exercise, BP monitoring, and appropriate antihypertensive treatment for individuals with hypertension.

The multifaceted interventions is comprised of the following components:

  1. To establish a BP management team led by family health instructor. The team members also include family leaders and village doctors.
  2. To conduct multifaceted intervention, which includes education for a healthy lifestyle, free provision of sodium substitute, weight management, physical exercise, BP monitoring, and appropriate antihypertensive treatment for individuals with hypertension.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The changes of systolic blood pressure from baseline to 6 months
Time Frame: 6 months
The systolic blood pressure changes from baseline to 6 months for all villagers, reported as the difference between intervention and control group.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The changes of diastolic blood pressure from baseline to 6 months
Time Frame: 6 months
The diastolic blood pressure changes from baseline to 6 months, reported as the difference between intervention and control group.
6 months
The changes of systolic blood pressure from baseline to 12 months
Time Frame: 12 months
The systolic blood pressure changes from baseline to 12 months, reported as the difference between intervention and control group.
12 months
The proportion of participants with antihypertensive therapy at 6 months
Time Frame: 6 months
The proportion of participants with antihypertensive therapy at 6 months
6 months
The proportion of participants with SBP<130 or DBP<80 mmHg at 6 months
Time Frame: 6 months
The proportion of participants with SBP<130 or DBP<80 mmHg at 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jun Cai, MD, Beijing Anzhen Hospital
  • Principal Investigator: Xin Du, MD, Beijing Anzhen Hospital
  • Principal Investigator: Craig S Anderson, MD, Institute of Science and Technology for Brain-Inspired Intelligence
  • Principal Investigator: Chao Jiang, MD, Beijing Anzhen Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 23, 2024

Primary Completion (Actual)

February 12, 2025

Study Completion (Actual)

July 28, 2025

Study Registration Dates

First Submitted

May 18, 2024

First Submitted That Met QC Criteria

May 18, 2024

First Posted (Actual)

May 23, 2024

Study Record Updates

Last Update Posted (Actual)

March 4, 2026

Last Update Submitted That Met QC Criteria

March 2, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HFP2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blood Pressure

Clinical Trials on Multifaceted intervention

Subscribe